Addex Therapeutics LtdADXNNASDAQ

Overview Intelligence Charts News Fundamentals

Latest News

globenewswire.com

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253.

defenseworld.net

Critical Analysis: Addex Therapeutics (NASDAQ:ADXN) & Aditxt (NASDAQ:ADTX)

Aditxt (NASDAQ: ADTX - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability. Valuation and Earnings This table compares Aditxt and

globenewswire.com

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C.

seekingalpha.com

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

globenewswire.com

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update.

globenewswire.com

Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025

seekingalpha.com

Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2025 Earnings Call October 1, 2025 10:00 AM EDT Company Participants Timothy Dyer - Co-Founder, CEO & Director Mikhail Kalinichev - Head of Translational Science Conference Call Participants Bob Pooler - ValuationLAB AG Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

globenewswire.com

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Invested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2025, and provided a corporate update.

globenewswire.com

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025.

globenewswire.com

Addex Appoints Bank of New York Mellon as Depositary Bank

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent.

globenewswire.com

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders.

globenewswire.com

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C and the partnering of key programs.

globenewswire.com

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM).

globenewswire.com

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2025 financial results and provided a corporate update.

globenewswire.com

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

globenewswire.com

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs.

globenewswire.com

Addex Convenes Annual General Meeting 2025

Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).

globenewswire.com

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies.

globenewswire.com

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors for the treatment of brain injury recovery.

seekingalpha.com

Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2024 Earnings Conference Call April 25, 2025 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Peter Ehrlich - AikenSalt Raghuram Selvaraju - HC Wainwright & Co Tim Dyer Hello everyone. I would like to thank you all for attending our 2024 Full Year Financial Results Conference Call.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance